The function of macroautophagy/autophagy during tumor initiation or in established tumors can be highly distinct and context-dependent. To investigate the role of autophagy in gliomagenesis, we utilized a KRAS-driven glioblastoma mouse model in which autophagy is specifically disrupted via RNAi against Atg7, Atg13 or Ulk1. Inhibition of autophagy strongly reduced glioblastoma development, demonstrating its critical role in promoting tumor formation. Further supporting this finding is the observation that tumors originating from Atg7-shRNA injections escaped the knockdown effect and thereby still underwent functional autophagy. In vitro, autophagy inhibition suppressed the capacity of KRAS-expressing glial cells to form oncogenic colonies or to survive low serum conditions. Molecular analyses revealed that autophagy-inhibited glial cells were unable to maintain active growth signaling under growth-restrictive conditions and were prone to undergo senescence. Overall, these results demonstrate that autophagy is crucial for glioma initiation and growth, and is a promising therapeutic target for glioblastoma treatment.
Suppression of autophagy impedes glioblastoma development and induces senescence
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INTRODUCTION
Glioblastoma multiforme (GBM) is the most common adult brain tumor and one of the most aggressive cancers with a median survival of approximately one year. 1 Understanding survival response processes in GBM that contribute to its resistance would be crucial for therapy. One such survival process is autophagy, a cellular catabolic pathway frequently activated upon various stresses encountered by the cell including nutrient deprivation and hypoxia. 2 During autophagy, cytoplasmic material is targeted for lysosomal degradation by a finely orchestrated series of vesicle formation and fusion events. A number of autophagy-essential protein complexes are required for the formation of a double-membrane structure, the phagohpore, that engulfs cytoplasmic materials, resulting in an enclosed vesicle called the autophagosome. 3 At the heart of the autophagy pathway lies a family of ubiquitin-like proteins, such as MAP1LC3/LC3 (microtubule-associated protein 1 light chain 3), essential for autophagosome maturation. Cytosolic LC3 (termed LC3-I) is recruited to the growing phagophore upon its ubiquitin-like conjugation to phosphatidylethanolamine forming LC3-II.
This reaction is catalyzed by the activity of E1-, E2-and E3-like enzymes, which are ATG7, ATG3
and ATG12-ATG5-ATG16L1, respectively. Autophagy activation can be sensed by the ULK (unc-51 like kinase) signaling complex comprised of the protein kinase ULK1 and several regulatory components including ATG13 and RB1CC1/FIP200 (RB1-inducible coiled-coil 1).
Increasing evidence has demonstrated that autophagy is closely associated with cancer. 2, 4 Autophagic degradation of cytoplasmic components can promote tumor cell survival by providing nutrient supply, or can suppress tumorigenesis by clearing toxic cellular materials that can otherwise be carcinogenic. Such dual effects of autophagy on cancer progression are most likely dependent on the tumor type, genetic composition and stage. Genomic studies of GBM patient samples revealed mutations in multiple signaling pathways, including gain-offunction mutations in the receptor tyrosine kinase (RTK)-RAS-class I phosphoinositide 3-kinase oncogenic pathway, 5 which modulate autophagy. 6 Furthermore, in cultured GBM cells, autophagy is frequently activated as a stress response upon treatment with therapeutic agents. 7 However, how autophagy affects GBM development in vivo has not been addressed.
Cellular and xenograft experiments suggest an important role of autophagy in GBM. 8, 9 However, these experiments utilize established GBM cell lines, and thus do not reflect the process of tumor initiation. or control shRNA (KRAS:shLacZ). Using this system, efficient gene knockdown (Fig. 1B ) and oncogene overexpression (Fig. 1C) can be achieved upon the infection of primary TVAexpressing glial cells (termed XFM cells) derived from uninjected mice. 12 Furthermore, shRNAmediated inhibition of Atg7, Atg13 or Ulk1 resulted in autophagy inhibition as assessed by endogenous LC3 lipidation, but maintained residual autophagic activity (Fig. 1D) .
Autophagy is required for GBM development.
To test the effect of autophagy inhibition on KRAS-mediated gliomagenesis, we performed intracranial injection of DF-1 cells expressing RCAS viruses into neonate mice.
Injection of DF-1 expressing KRAS:shLacZ RCAS viruses resulted in tumor formation in approximately 60% of the mice within 6 weeks after injection ( Fig. 2A-B (Fig. 2C) .
Similarly, there was no difference in NES/nestin (marker of GBM) or MKI67/Ki67 (proliferation marker) staining (Fig. 2D) . Next we examined whether KRAS:shAtg7-derived tumors exhibited efficient reduction of ATG7 protein levels. Interestingly, immunohistological staining showed comparable ATG7 levels between shAtg7-and shLacZ-expressing tumors, suggesting that the tumor cells bypassed the Atg7 shRNA effect (Fig. 2E) . We further confirmed the specificity of the anti-ATG7 antibody by staining mouse embryonic fibroblasts (MEFs) derived from wild type or atg7 knockout mice (Fig. 2F) . Overall, these observations further support the conclusion that the expression of autophagy-essential genes is required for GBM formation in the KRAS-RCAS/TVA model. . 1B) . We observed no growth defects upon autophagy inhibition in cells grown under normal culture conditions in monolayer.
Autophagy is required for KRAS-driven oncogenic growth of glial cells.
Interestingly, when cells were seeded in anchorage-independent conditions in soft agar, colony formation was strongly reduced in KRAS cells co-expressing shRNA targeting Atg7, Atg13 or Ulk1 compared to KRAS:shLacZ expressing cells (Fig. 3A) . Therefore, autophagy appears to be critical for KRAS-driven glial transformation. Furthermore, we tested whether autophagy is We further tested the underlying mechanism for the lack of clonogenic growth in autophagy-inhibited cells by analyzing growth signaling and survival pathways. We observed neither morphological changes indicative of cell death induction in cells cultured under lowserum condition (0.1% FBS) nor CASP3/caspase-3 activation, indicating that the difference in growth capacity was not due to apoptotic cell death (Fig. 3D ). Next, we tested whether growth Overall, the above results strongly suggest that autophagy is required to maintain growth signaling pathways in cells deprived of growth factors or grown under hypoxia.
Autophagy inhibition induces senescence and reduces metabolic activity under low serum conditions.
We further sought to characterize the consequences of autophagy inhibition in cells grown under suboptimal culture conditions. Having observed that in the absence of autophagy cells failed to recover after being cultured in low-serum media for 14 days (Fig. 3B) , we examined whether cells underwent irreversible growth arrest. To do so, we measured senescence-associated β-galactosidase (SA-GLB1) activity as an assay for cellular senescence. As shown in Fig. 4A , autophagy inhibition resulted in a significant increase of senescent cells in were elevated in KRAS:shAtg7 cells compared to KRAS:shLacZ cells (Fig. 4C-D) . These results suggest that when autophagy is defective, cells are more prone to undergo senescence.
Interestingly, under low serum conditions, activation of TRP53/p53 was not detected, suggesting that in this context senescence may occur independently of TRP53 16, 17 (Fig. 4C ).
These observations highlight the importance of autophagy in maintaining cell cycle progression in culture following growth factors withdrawal in KRAS-transformed cells.
We further sought to measure whether the metabolic activity of KRAS-expressing cells differed in the absence of autophagy in growth-arrested cells during prolonged serum starvation (Fig. 4E) . When cells were grown under normal growth conditions (10% FBS), there was no significant difference in glucose, glutamine and pyruvate consumption or lactate production between the 2 cell types (Fig. 4F) . Under conditions of serum starvation, however, uptake of these nutrients was markedly reduced in autophagy-deficient cells indicating that overall biosynthetic activity in these cells was lower. Lactate production was also lower in KRAS:shAtg7-expressing cells, indicating reduced aerobic glycolysis. Overall, these results indicate that autophagy acts as a stress response pathway and is required to bypass senescence and maintain metabolic activity in growth-arrested conditions.
In this study, we demonstrate that RNAi-mediated suppression of autophagy impedes tumor incidence in a KRAS-driven, RCAS/TVA GBM model. This is in agreement with previous studies where suppression of autophagy by genetic deletion restricts growth of KRAS-and BRAF-driven tumors of the lung, pancreas and skin. [18] [19] [20] Further supporting our findings is the observation that tumors developing from KRAS:shAtg7 injections retain Atg7 expression. Loss of RNAi repression effect may be due to either silencing of the shRNA expression or additional mutations that render resistance to the shRNA.
The RCAS/TVA mouse model is a unique system to study gliomagenesis based on somatic gene transfer (using RCAS viruses) into a specific cell type (engineered to express viral TVA receptor). 10 Unlike xenograft models that utilize established cancer cells, this genetically engineered mouse model allows for the assessment of tumor initiation in the presence of a functional immune system. In addition, xenograft experiments rely on the injection of a large number of cells into the recipient animals which differ considerably from the process of tumor development generally involving the transformation of a single or few cells. 21 Indeed, considerable differences are observed when assessing the role of autophagy in GBM using the RCAS/TVA mouse model presented here and previously published xenograft studies. Xenograft studies using GBM cell lines show that autophagy inhibition cooperates with drug treatment to restrict cell growth but has no effect on tumor growth in the absence of treatment. 8, 9 However, our studies indicate that autophagy inhibition in the absence of drug treatment can affect tumor development (Fig. 2) 27 This may imply that, in a similar fashion, the absence of glycolysis in autophagy-defective cells may contribute to their inability to proliferate when restimulated with full growth medium as observed in our system. It remains to be defined whether the role of autophagy in maintaining cell growth and metabolic activity is required for gliomagenesis in vivo. Mouse models allowing conditional autophagy inhibition after tumor establishment will be useful for this purpose.
Our study is the first to demonstrate the effect of autophagy inhibition by RNAi on gliomagenesis in a genetically engineered mouse model. A recent study showed that adult mice with conditional whole body deletion of Atg7 live for 2-3 months due to selective tissue damage. 28 However, in this model, complete inhibition of autophagy in mice with lung tumors induces tumor regression within 5 weeks, suggesting that a therapeutic window exists and can be exploited. 28 Additionally, when autophagy is significantly inhibited but not completely ablated, an anti-tumorigenic effect could already be achieved, as demonstrated by RNAi-based autophagy inhibition in our GBM mouse models. A partially inhibited autophagy pathway is likely to maintain the homeostatic function of autophagy in normal tissues during prolonged treatment, thus avoiding the lethal effect of complete, whole body elimination of autophagy function.
MATERIALS AND METHODS
Cell culture and treatment.
DF-1 chicken fibroblasts (ATCC, CRL-12203) and glial cells derived from the RCAS mouse
model expressing TVA receptor XFM, 12 were cultured in DMEM (Life Technologies, 41966029 supplemented with 10% FBS, L-glutamine (2 mM), penicillin (10 units/mL) and streptomycin (0.1 mg/ml).
For amino acid starvation experiments, cells were grown in DMEM lacking amino acids and serum for 2 h prior to harvest, as described previously. 29 The lysosomal inhibitor, bafilomycin A 1 (Sigma, B1793), was added as indicated at a final concentration of 20 nM for 2 h.
Staurosporine (STS; Sigma, S5921) was added to cells for a final concentration of 1 µM for 16 h.
Western blot and antibodies.
For western blot analyses, cell lysates were prepared in RIPA buffer (10 mM Tris pH 7.4, 100 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1 mM ethylene glycol tetraacetic acid, 0.1% sodium dodecyl sulfate, 1% Triton-X100 [Sigma, T9284], 1 mM 2-mercaptoethanol, 0.5% sodium deoxycholate and 10% glycerol) and analyzed by SDS-PAGE as described previously.
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The following antibodies were used: anti-LC3 (Sigma, L7543); anti-ACTB/beta-actin (Sigma, 
Injections.
All animal experiments were done in accordance with protocols approved by the Institutional Animal Care and Use Committees of Memorial Sloan Kettering Cancer Center and followed NIH guidelines for animal welfare. The RCAS/TVA system used in this work to induce gliomas in vivo in immunocompetent mice has been described previously.
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N/TVA;cdkn2a/ink4a-arf) -/-
;Pten fl/fl mice were used for the RCAS mediated gliomagenesis in this study. 13 Briefly, DF-1 cells were transfected with the relevant RCAS viral plasmid using Lipofectamine2000 (Invitrogen, 11668019) according to the manufacturer's protocol. The cells were regularly maintained for at least 3 passages for propagation of the RCAS viruses to entire cells. Cells were then used for injection into murine brain. Newborn pups were injected intracranially with 1 μL of ~1x10 5 DF-1 cells. Then mice were monitored until they developed symptoms of GBM such as lethargy, poor grooming, weight loss, dehydration or macrocephaly.
GBM incidence or absence was confirmed by H&E staining of brain sections in all injected animals. Kaplan-Meier analysis demonstrating symptom-free survival in murine gliomas was performed using the Prism software (GraphPad).
Vector constructs.
For the generation of the RCAS-shRNA vector, shRNAs were initially assembled in the pSUPER.retro vector (OligoEngine, VEC-PRT-0002). The shRNAs containing the H1 promoter were PCR-amplified and then inserted into the RCAS-Y vector (generated and provided by Dr Yi
Li, Baylor College of Medicine, Texas) 31 using NotI and PacI restriction sites. KRAS was subsequently cloned using NotI restriction sites. The shRNA target sequences are as follows:
Immunocytochemistry.
Mouse brains harvested from animals were fixed in 10% formalin for 24-72 h and then transferred to 70% ethanol. Samples were then paraffin-embedded, sectioned and stained with 
Colony formation assay.
XFM cells were seeded in 6-cm dishes; 24 h later cells were cultured in 0.1% FBS for 2 weeks (with medium replenished after 1 week) followed by growth in 10% FBS for a further 1 week. Cells were then fixed with 10% formaldehyde and stained with Giemsa (Sigma, GS500) to visualize colonies.
Hypoxia.
For hypoxia experiments, cells were incubated in a Whitley H35 Hypoxystation set to 37°C and 0.5% O 2 . 72 h later, cells were lysed inside the Hypoxystation and analyzed by western blotting.
Soft agar assay.
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XFM cells were seeded at 10,000 cells/well in a 6-well dish. Cell suspension (final volume 1.5 mL) containing 0.4% low gelling agarose (Sigma, A4018) in full growth DMEM was overlaid with a layer of 0.5% agarose and left to solidify at 4°C. Cells were then incubated at 37°C, fed weekly with 0.4% agarose-containing DMEM and analyzed after ~3 weeks by staining with 0.02% Iodonitrotetrazolium chloride (Sigma, I10406). Colonies were quantified using an Optronix Gelcount (Oxford Optronix). All assays were conducted in triplicates in 3 independent experiments.
Senescence-associated β-galactosidase assay (SA-GLB1). Images of cells were taken using a Nikon Digital Sight DS-L3.
BrdU incorporation assay.
For the BrdU incorporation assay, cells were pulsed with 50 μM BrdU (Sigma, B5002) for acetonitrile). Metabolites were eluted into a Q-Exactive mass spectrometer (Thermo Fisher Scientific) using a flow rate of 300 µl/min. Metabolite masses were acquired in negative mode within the range of 78-250 m/z. Relative metabolite abundance was then determined by integrating the ion peak area (Quan Thermo Xcalibur) and normalized to cell number.
Statistical analyses.
All data are presented as the mean ± SEM. The statistical significance was evaluated using two-tailed, unpaired student's t-test. Percentage tumor-free survival Kaplan Meier curve was analyzed using Log-rank Mantel-Cox test (Graphpad Prism software). The data were considered significant when the P value was less than 0.05 (*). 
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